he sirolimus-eluting stent (SES; CYPHER ® , Johnson & Johnson Corp) is a closed-cell type stent and is currently the sole drug-coated stent approved for use in Japan. SES implantation has been proven to markedly reduce the incidence of restenosis. In a randomized study with the sirolimus-eluting Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions (RAVEL), there were no cases of restenosis with the SES. 1,2 On the other hand, in the sirolimus-eluting Bx Velocity balloon-expandable stent trial (SIRIUS), restenosis occurred in 9% of cases in the SES group. [3] [4] [5] Technical success rates and outcomes of stenting are affected by method and technique, but there are few reports on the safety and outcomes of SES in Japan. 6, 7 We have conducted cooperative research with 6 intermediate-scale facilities in the Kansai area investigating implantation of success rates and mid-term outcomes of SES and the present study was conducted to investigate the impact of SES in the 'real world'.
Methods

Subjects
Four hundred and 2 lesions in 297 patients treated with SES at 6 facilities (annual percutaneous coronary intervention caseloads ranging from 100 to 350) in the Kansai district area between May 2004 and February 2005 were selected as subjects. The SES was not used in all the lesions and there was no randomization. If the clinician determined a lesion to be significant, it was selected as a target lesion and the patient was enrolled without exclusion.
Treatment and Examination Method
There were no procedural restrictions regarding stent implantation. Procedures prior to stent placement, post-dilatation and selection of stent size and length were decided by the person in charge of each facility. However, administration of aspirin and ticlopidine was required as post-procedural antiplatelet therapy. In principle, late coronary angiographic follow-up was conducted at approximately 6 months post-procedure. This protocol was conventional practice at all the participating facilities, so special informed consent was not required. Each patient was informed of the purpose and method of the study, stent efficacy and the need for long-term treatment and gave verbal, not written, informed consent.
Evaluation Method
Lesions were evaluated by quantitative coronary angiography (QCA) using the MEDIS cardiovascular analysis system (QCA-CMSR). Initial procedural success was defined as 50% or less residual stenosis rate on QCA and late restenosis was defined as 50% or greater restenosis. 
Statistical Analysis
In the statistical analysis, the chi-square test was used for comparison between groups, the t-test for continuous variables, and logistic regression analysis for multivariate analysis. Analysis was conducted with chronic restenosis as the dependent variable and each parameter as an independent variable, and a p-value <0.05 was considered significant.
Results
Patients' Background
The background of each of the subjects at the time of enrollment is shown in Table 1 ; 74.7% of the subjects were in Canadian Cardiovasular Society classification I or II and 25.3% in classification III or IV; coronary risk factors included diabetes mellitus in 47.8%. Past history of myocardial infarction was found in 44.4%, past history of coronary artery bypass grafting in 9.4%, and deteriorated cardiac function with ejection fraction less than 40% in 19.5%. Patients with lesions in 2 or more vessels accounted for 48.8%. Enrollment was established at the time when a SES package was opened, and each primary operator filled in a standard case report form, which was collected later.
Lesion Background
Target lesion background is shown in Table 2 . Left main trunk lesions accounted for 1.2%. American Heart Association classification B2 or C was observed in 64.9% and chronic total occlusion (CTO) lesions in 3.0%. Bypass graft lesions were found in 3.4%. The reference diameter of the target vessel was 2.81±0.48 mm (continuous variables are shown as mean ± standard deviation).
Procedures, Devices Used and Stent Dilation Pressure
As the pre-stent implantation procedure, balloon expansion was performed in 350 lesions, percutaneous transluminal coronary rotational atherectomy in 11 lesions, and directional coronary atherectomy in 1 lesion. A direct stent implantation procedure was performed in 40 lesions. The average stent diameter was 2.94±0.36 mm, and average stent length was 20.0±3.4 mm. In this study, each lesion was covered with a single stent. Breakdowns are shown in Fig 1. Stent diameter used and stent length reflect the dimensions indicated on the package, not actual in-situ diameter and length after deployment. In 54 lesions, another high-pressure balloon catheter was used for the post-stent implantation procedure. Final maximum stent dilatation pressure was 15.8±2.24 atm.
Initial Stage Outcomes
The initial procedural success rate was 99.5%; in the 2 unsuccessful cases the stent was not able to cross the lesion. On QCA, minimum vessel diameter before treatment was 0.75±0.52 mm and 2.74±0.46 mm after treatment. 
Late Stage Outcomes and Analysis
The main complications included subacute thrombosis (SAT) in 1 patient, non-cardiac death in 8 patients, and cardiac death in 1 patient (Table 3) . Three hundred twentythree lesions in 245 patients underwent late angiographic follow-up. The follow-up rate was 82% of patients and 80% of lesions. The observation period was 182±35 days, the restenosis rate 4.0%, and target lesion revascularization rate 3.7% (Fig 2) . Changes in reference diameter and minimum vessel diameter are shown in Fig 3. Mean late minimum vessel diameter was 2.58±0.62 mm.
Comparisons of late restenosis between patient subgroups are shown in Table 4 . Chronic hemodialysis treatment was a significant risk factor; other items were not significant. In this study, there was no restenosis in acute myocardial infarction patients. A comparison of late restenosis and lesion subgroup is shown in Table 5 . In the comparison between groups, the following 6 items were significant factors: calcification, non-CTO (total occlusion except CTO), ostial lesions, lesions kinked >45°, right coronary artery (RCA), and lesions at the ostium of the RCA. In all 5 cases of restenosis at the ostium of the RCA, the stents protruded out of the RCA and restenosis lesions were found in the stent bodies. Other than these 5 RCA ostium lesions and 1 case of SAT, 5 restenosis lesions were found at stent edges and 1 in the stent body. In 1 case, the restenosis site could not be determined because of total occlusion. The relationship between late restenosis and procedural variables, stent used, and QCA before and after treatment, are shown in Table 6 . There was no significant difference between stent diameter used, stent length used, minimum vessel diameter immediately after treatment, and maximum dilatation pressures. As for the restenosis rate, there was no significant difference between facilities (p=0.47). Multivariate analysis used the variables that had become significant factors in late restenosis. The univariate analysis is shown in Table 7 . The factor most predictive of late restenosis was RCA ostial lesion, followed by chronic dialysis treatment.
Discussion
SES implantation has been proven in randomized studies to markedly reduce the incidence of restenosis; however, those studies treated relatively noncomplex lesions referred for elective intervention. 1 
Deliverability
In the present study there were no exclusion criteria based on vessel diameter and/or lesion length, the mean reference diameter of the target lesion was small, the ratio of peripheral lesions was high, and lesion profiles were comparatively severe, 2 which may be because the operators at each facility knew that SES deliverability is excellent. 8, 9 The high initial success rate of SES in this study may indicate the excellent deliverability of the stent delivery system.
Restenosis
In many previous studies of bare-metal stents, reference diameter, selected stent diameter, minimum vessel diameter immediately after treatment, and maximum stent dilatation pressure were factors influencing late restenosis rates. 10, 11 However, in the present study these were not significant factors for late restenosis. Restenosis at the stent edges and SAT, which became an issue in early overseas studies on SES, [12] [13] [14] were not problematic here. One reason may be that the late restenosis rate in our study of SES was low, and another may be that the operators at the facilities participating in this study had extensive experience with the Bx Velocity stent, a bare-metal stent that uses the same metal and design as the SES, and therefore were able to deploy SES more effectively. 9, 15 Specifically, complete coverage of the lesion and high-pressure dilatation may have contributed to the good results achieved. 9, [16] [17] [18] [19] Another reason may be that, based on experience with the Bx Velocity stent, the SES was not used in this study for lesions that were suspected from the start to have a high probability of perforation (including highly kinked lesions). Factors that were significant in the late restenosis rate in the present study have been cited as significant in late restenosis in bare metal stent studies in the past. [20] [21] [22] As shown in Table 5 , it may be contrary to expectation that non-CTO, but not CTO, was a significant factor and we postulate that the reason was incomplete coverage of the lesion, because immediately after recanalization of a non-CTO lesion the extent of the lesion is not distinct, and operators tend to avoid using unnecessarily long stents. In 4 cases of restenosis of non-CTO lesions, 3 showed restenosis lesions at the distal stent edge and 1 showed recurrence of total occlusion. Although instent restenosis lesions (ISR) are listed frequently as a factor in late restenosis in previous bare metal stent studies, in the present series it was not involved at all. The essential component of ISR is mainly considered to be intimal hyperplasia. If the basis of the superiority of the drug-eluting stent over the bare-metal stent lies in inhibition of intimal hyperplasia, there is rationalization for this outcome. 15, 23, 24 On the other hand, physical causes other than intimal hyperplasia may be involved in RCA ostial lesions and in late restenosis in chronic dialysis patients. We postulate that in RCA ostial lesions mechanical factors at the aorto-coronary junction may be involved. It is necessary to investigate and compare these with left main coronary ostia in order to make some inference concerning the interaction of sirolimus with the aorta. 25 With regard to chronic dialysis patients, we thought that biochemical factors may become worse with later stage outcomes. Abnormal platelet function, high oxidative stress and underlying unsettled hypertension are suspected to participate in restenosis. 26 These observations suggest that there are lesions that cannot be resolved even with SES.
Study Limitations
Although the study design was determined before treatment of patients began, it was not a completely prospective study. The most problematic point is that stent selection was left up to the person in charge of each facility. The usage rate of SES in patients who underwent stenting during the study period was in fact different between facilities. Additionally, QCA was not performed by an independent core laboratory.
Conclusion
SES showed a high initial success rate. The restenosis rate was excellent, and was not influenced by stent length or target vessel diameter. Nevertheless the existence of patient and lesion subgroups that are not resolved by SES is suggested. RCA ostial lesions and chronic dialysis are factors correlated with restenosis and are issues that remain to be solved in the future.
